Cogent Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everyone. Welcome to the third and final day of the Morgan Stanley Healthcare Conference. Thanks, everyone, for attending.
My name is Jason Russell with the Healthcare Investment Banking team at Morgan Stanley. Before I jump in and introduce Andy, a quick research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/research disclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So briefly, on stage here with Andy Robbins, President and CEO of Cogent. Cogent is a clinical-stage company focused on developing precision therapies for genetically-defined diseases. Most advanced clinical program is bezuclastinib. I'm going to try and pronounce that correctly, which is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation, as well as other KIT exon 17 mutations.
Bezu is being studied in systemic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |